Who we are


Management Team

Andrew Mearns-Spragg Professor Andrew Mearns Spragg
Founder, Chief Scientific Officer linkedin Logo MORE Jellagen Arrow
Thomas-Paul Descamps Thomas-Paul Descamps
Chief Executive Officer linkedin Logo MORE Jellagen Arrow
Dr Andy Weymann MD MBA
Chief Medical Officer linkedin Logo MORE Jellagen Arrow
Steve Fairey Stephen Fairey
Chief Financial Officer MORE Jellagen Arrow
Almero Barnard
Chief Manufacturing Officer MORE Jellagen Arrow

Board

GreggWeb Gregg Sando
Chairman of the Board, Non-Executive Director linkedin Logo MORE Jellagen Arrow
Stephane Thiroloix Stéphane Thiroloix
Non-Executive Director linkedin Logo MORE Jellagen Arrow
Berent Wallendahl Berent Wallendahl
Non-Executive Director

linkedin Logo MORE Jellagen Arrow
Andrew Mearns-Spragg Professor Andrew Mearns Spragg
Founder, CSO, Executive Director

 linkedin Logo MORE Jellagen Arrow
Thomas-Paul Descamps Thomas-Paul Descamps
CEO, Executive Director linkedin Logo MORE Jellagen Arrow
Steve Fairey Stephen Fairey
CFO, Board Observer MORE Jellagen Arrow

Team

Dr Andy Weymann MD MBA Team
Chief Medical Officer linkedin Logo MORE Jellagen Arrow

Scientific Advisory Board

Professor Andrew Mearns Spragg
Founder, CSO, Science Advisory Board Chairman linkedin Logo MORE Jellagen Arrow
Emeritus Professor Sheila MacNeil
Scientific Advisory Board Member MORE Jellagen Arrow
Dr Mike Barbeck
Scientific Advisory Board Member MORE Jellagen Arrow
Dr Andy Weymann MD MBA
Scientific Advisory Board Member MORE Jellagen Arrow
Dr Alex Pretsch
Scientific Advisory Board Member

 MORE Jellagen Arrow
Dr Tim Morley FRCPath
Scientific Advisory Board Member

 MORE Jellagen Arrow
Dr Serban San-Marina
Scientific Advisory Board Member

 MORE Jellagen Arrow

Our Investors

Angels Invest Wales
MORE Jellagen Arrow
Development Bank of Wales Development Bank of Wales
MORE Jellagen Arrow
Newable logo Newable
MORE Jellagen Arrow

Press Releases

Jellagen and Cellaria Inc develop next-generation models for cancer research

New partnership between Jellagen and Cellaria Inc. offers a paradigm shift in collagen chemistry to develop next-generation models for cancer research

 View PDF Jellagen Arrow

SMART Cymru funding enables development of world-first Jellyfish bio-ink for tissue regeneration

Jellagen and Copner Biotech ink partnership following SMART Cymru innovation funding award of £123,724

 View PDF Jellagen Arrow

Jellagen adds Professor Sheila MacNeil to Scientific Advisory Board

Professor Sheila MacNeil is Emeritus Professor of Tissue Engineering at the Department of Materials Science and Engineering, University of Sheffield

View PDF Jellagen Arrow

Jellagen signs Research Partnership Agreement with IFREMER – The French Institute of Research and Marine Exploitation

The partnership agreement enables Jellagen privileged access to Ifremer’s proprietary technology on testing new marine derived natural products for medical research.

 View PDF Jellagen Arrow

Jellagen launches JellaGel™

The first Collagen Type 0 Hydrogel taking on the market leading Extracellular Matrix.

 View PDF Jellagen Arrow

Jellagen Boosts Scientific Advisory Board with New Appointments

Jellagen Boosts Scientific Advisory Board with New Appointments Dr Mike Barbeck and Dr Andy Weymann

 View PDF Jellagen Arrow

Jellagen® extends coverage in Asia Pacific with new distributor agreements

Jellagen signs three new partner and distributor agreements to cover the APAC region

 View PDF Jellagen Arrow

Jellagen® announces collaboration with Mayo Clinic

Jellagen has entered into a license agreement for an exclusive grant to patent rights with Mayo Clinic for the development in treatment of vocal cord paralysis.

 View PDF Jellagen Arrow

Jellagen® successfully supports the culture of Microglia Cells

Microglia Cells on Jellagen® demonstrated a more ramified “microglial-like” cell morphology compared to cells cultured on mammalian Rat Tail Collagen I and Laminin-511.

 View PDF Jellagen Arrow

Jellagen® announces £1.9m seed financing

Jellagen® announces £1.9m seed financing to develop products for therapeutic and medical device applications

 View PDF Jellagen Arrow

Jellagen® announce the appointment of new Chairman of the Board, Gregg Sando.

Gregg replaces Stephane Thiroloix who will remain as a non-executive director at Jellagen®. Gregg founded one of the first cancer immunotherapy biotech companies in 2005 and has pioneered the commercialization of innovative cell therapies for oncology and infectious diseases.

 View PDF Jellagen Arrow

Jellagen® 3D Systems Support Ovarian Cancer Cell Line Proliferation

Jellagen jellyfish collagen 3D systems support ovarian cancer cell line proliferation, confirming suitability for advanced cell culturing applications.

 View PDF Jellagen Arrow

Le collagène de méduse s’apprête à révolutionner la culture cellulaire in vitro et la médecine régénérative

Jellagen®, jeune entreprise britannique basée à Cardiff spécialisée en biotechnologie marine lance cette semaine JellaGel ™, le premier Hydrogel de collagène de méduse purifié, conçu pour la culture cellulaire 3D et l’ingénierie tissulaire

 View PDF Jellagen Arrow

Jellagen announces new CEO

Marine Biotechnologies firm Jellagen announces the appointment of a new CEO

 View PDF Jellagen Arrow

Jellagen on course for accelerated growth

Marine Biotechnologies firm Jellagen on course for accelerated growth thanks to £3.8m funding from Newable Private Investing, Development Bank of Wales and Angel Investors

 View PDF Jellagen Arrow